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Introduction 
Following animal experiments supporting the feasibility of heart transplantation, 
the first human heart transplant was performed In December, 1 9 6 7 , In Capetown, South 
Africa. The first successful operation In the United States was in May, 1968. Although 
approximately 100 transplants were performed worldwide in 1968, there were few long 
term survivors. Between 1969 and the mid 1 9 7 0 ' s , only a small number of transplants 
were performed due to the limited ability to combat rejection and infection; the two main 
causes of mortality in cardiac transplantation. By 1980, only 400 heart transplants had 
been (tone worldwide with over half of these performed at Stanford, In 1968, Stanford's 
one-year patient survival rate was only 2 2 1 , but by 1 9 7 9 it had increased to 6 7 $ , a 
success rate that exceeded the expected survival of patients with end stage heart failure. 
1,2 
A great (teal of this Increased success was directly attributable to better agents for 
Immunosuppression such as ant (thymocyte globulin (ATS), which was acted to the 
Stanford protocol In 1972. Also, the use of myocardial biopsy to detect early rejection 
allowed appropriate therapy to be initiated before overt clinical signs of rejection were 
seen. 1 
Prior to 1980, most centers used some combination of azathioprine, 
corticosteroids, and ATG for immunosuppression. When Cyclosporin A (CyA) was 
Introduced in 1980, It was perceived as a significant advancement in immunosuppressive 
therapy since it was thought to be both more effective and less toxic than other agents 
available at that time. The development of cyclosporin created renewed Interest In 
cardiac transplantation and the field grew rapidly, According to recent figures, the 
number of U.S, centers increased to 7 4 by 1985 and more cardiac transplants were 
performed in the U.S. during 1 9 8 0 - 8 2 than had been done in all previous years. 2> 3 > 4 
2 
The Utah Cardiac Transplant Program ( U C T P ) was started in March of 1985, As 
of September 1 , 1 9 8 6 , 5 0 heart transplants had been performed. Although some episodes 
of rejection have occurred, the patient survival rate is currently 9 7 S at one year- the 
best in the country. The immunosuppressive regimen has changed during this period of 
time with the addition of randomized trials using vincristine and Orthoclone 0KT3 ® 
(0KT3) combined with the standard regimen of cyclosporine, AT6, corticosteroids and 
azathioprine, 
In anticipation that other institutions will desire to duplicate one of these 
regimens, a complete descriptive analysis of the therapeutic and toxic effects of these 
immunosuppressive regimens is warranted. 
Although exceptions are made to these guidelines, the general indications for 
cardiac transplantation are end stage heart disease, (NYHA Functional Class III or IV) 
unresponsive to conventional therapies, with an expected survival time limited to weeks 
or months, Patients with severely debilitating angina secondary to inoperable coronary 
artery disease (CAD) are also candidates. The etiology for heart failure In many patients 
is coronary artery disease or Idiopathic cardiomyopathy. 
Ideally, the patient should be under the age of 65 and In otherwise good health, 
Some of the relative contraindications for transplantation include Insulin dependent 
diabetes, severe peripheral vascular disease, significant renal dysfunction, and 
psychosocial abnormalities, Patients should be free of fixed pulmonary hypertension and 
have no currently active infectious process or active peptic ulcer disease, 1 « 2 , 4 
Although some controversy exists, a correct match of donor and recipient may also be 
important for the success of the transplant. 5 Although most patients (to well, should a 
positive cross match occur, the immunosuppressive management strategy for that patient 
can be altered accordingly. In practice, ABO typing, height, weight, and echocardiography 
are the criteria used to determine donor compatibility. The donor should also have no 
history of heart disease or prolonged cardiac arrest requiring prolonged periods of 
intravenous pressor support. 1 
Several Immunosuppressive regimens exist and all may incorporate some 
combinstion of corticosteroids, cyclosporin, azathioprlne and ATG. The protocol with the 
longest history of use was developed at Stanford. The original Stanford protocol (circa 
1 9 7 0 ) consisted of azathioprlne, corticosteroids and ATO, When CyA was added in 1980, 
azathioprlne was dropped from the regimen, The standard UCTP protocol contains major 
changes when compared to Stanford's. The use of corticosteroids and two randomized 
studies with vincristine (VCR) and Orthoclone 0KT3® (0KT3) make the UCTP protocol 
radically different from protocols of other programs. 
The UCTP uses "triple therapy" for initial immunosuppression (CyA, 
azathioprlne, corticosteroids), but the goal of discontinuing maintenance steroids is a 
unique distinction, The UCTP now uses a pulse dose of oral steroids Immediately after 
transplant, tapering the patient off steroids during the maintenance phase providing 
rejection has not occurred in three successive biopsies [Appendix I]. Protocols which use 
combined therapy provide synergistic immunosuppression and allow smaller doses of each 
agent to be used, resulting in an overall decrease in toxicity and Increase in 
immunosuppressive effect, 7 
In order to follow the rationale for use of these agents it is also Important to 
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distinguish whether these agents are used in (a.) early post-operative prophylaxis to 
prevent acute rejection, ( b . ) treatment of acute rejection, (c .) chronic maintenance 
immunosuppression. A certain amount of overlap exists between the drugs which fall into 
these three categories. 
AGENTS U$Ep IN PROPHYLAXIS FOR ACUTE REJECTION; (ATS.VCMKT?) 
m 
Antithymocyte globulin (Atgam®) contains T cell antibodies and is a potent agent 
for eliminating the circulating T cell population. ATG may possess activity against 
precursor lymphocytes and possibly induces suppressor cell activity. This agent is not as 
specific in activity as CyA or 0KT3 since it contains some clinically undesirable antibodies 
against other formed elements in the blood, such as platelets. Monitoring ATG effect is 
done by measuring E. rosettes and targeting for less than < 1 0 1 . Atgam® is derived from 
horse serum and therefore patients may have severe reactions to the immunoglobulin. 
Other general side effects may Include serum sickness reactions, anemia, and 
thrombocytopenia, 1 • 8 
Vincristine 
Vincristine is a cell-cycle specific agent which causes metaphase arrest and 
blockade of mitosis In the proliferating cell. Intracellular^, It binds to tubulin and 
prevents the proper division of chromosomes, VCR possesses cidal activity which appears 
to be relatively specific for lymphocytes and lymphoblasts 6 . 
The rationale for using vincristine in early rejection prophylaxis comes from 
animal models which have demonstrated a favorable effect after bone marrow 
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transplantation and from suggestions that rejection after aritlthymocyte therapy may be 
due to T cell rebound. 6 VCR represents a possibly effective agent with a very different 
side effect profile from other immunosuppressants alreacV In use. 
Vincristine's major toxicity is peripheral neuropathy which appears to be dose 
related. It also causes gastrointestinal effects such as severe constipation in about 
one-half of patients. Paralytic ileus has also occurred, ^ 
o m 
Orthoclone 0KT3® (muromonab CD3; OKT3) is a murine monoclonal antibody 
recently approval by the FDA for use in acute rejection of renal allograft transplants. It 
is now being tested for use In the prophylaxis and treatment of acute rejection in other 
organ transplantations. 
O K I 3 possesses activity against a cell membrane determinant (CD3 antigen) of 
peripheral T cells, acting preferentially against them, while possessing no activity 
against B cells, granulocytes, monocytes or other human tissues and cells. When 0KT3 
interacts with the T cell and removes the antigen recognition apparatus (changing It from 
CD3+ to C D 3 - ) the T cell will remain Inactive in the presence of foreign antigen1 
OKT3 appears to possess a biphasic effect In which it initially destroys per ipheral 
T cells and then removes the antigen recognition apparatus from remaining T cells, 
Monitoring the effects of 0KT3 are done by measuring peripheral T cell populations. 
Typically, T3 positive cells will be reduced to < 1 % of the lymphocyte population while a 
patient receives 0KT3. 1 0 If the number of T3 positive cells exceeds of the total 
lymphocyte count during therapy, a sensitization reaction has probably occurred and 
indicates antibody formation against 0KT3. Co-administration of low-dose corticosteroids 
6 
is done In order to try and prevent this sensitization reaction. 
Several clinical trials In the renal transplant population indicate that 0KT3 1s a 
v e r y effective and safe agent for reversal of acute rejection episodes and recently, 
effectiveness has been demonstrated for early prophylaxis against rejection In renal 
allograft transplants. 1 1 
The side effect profile of 0KT3 manifests in two general categories. The most 
serious reaction, pulmonary edema, may preferentially occur in those patients with 
preexisting fluid overload as opposed to the euvolemlc patient. It is thought that this 
reaction Is due to mediators released from T cells when therapy with 0KT3 is s t a r t e d . 1 ' 
The second type of adverse reaction involves a complex of symptoms resembling a 
hypersensitivity reaction. Fever, gastrointestinal (nausea, diarrhea, vomiting) and 
respiratory (dyspnea, wheezing) symptoms comprise this reaction. This side effect has a 
high rate of occurrence and usually begins within 4 5 - 6 0 minutes after the first one or 
two doses. It is responsive to antihistamine and steroid therapy. This symptom complex 
1s also thought to be due to mediators released from T cells and is not a true 
hypersensitivity reaction as can occur with ATG, 1 1 , 1 2 
Antibodies to 0KT3 were demonstrated in approximately 8 0 1 of patients In one 
trial although no adverse reactions were described. 1 1 This finding has not led to a 
significant number of patients who are refractory to 0KT3 therapy due to inactlvatlon of 
the drug. 
The UCTP has conducted the first complete trial of 0KT3 (vs. ATG) for early 
prophylaxis of rejection in cardiac transplantation. 
7 
AGENTS USED IN TREATMENT OF ACUTE REJECTION: (ATO. OKT3. Steroids) 
Corticosteroids 
These agents are Included In some fashion In every Immunosuppressive protocol, 
Steroids directly inhibit antigen driven T cell proliferation and are cytotoxic to the 
lymphocyte cell line, Similarly to cyclosporins, corticosteroids are thought to Inhibit the 
Interleukln ( I L ) dependent rejection drive although they act one step earlier in the cycle 
than CyA and inhibit the release of I L - 1 . Therefore, a synergistic response Is created 
with the combination of cyclcsporine and steroids. ® 
Although they are effective immunosuppressants, long term corticosteroid 
therapy has major drawbacks associated with it due to the many side effects such as 
hypothalamie-pltultary-adrenal ( H P A ) axis suppression, fluid and electrolyte 
disturbances, osteoporosis, cataracts, hirsutism, hyperglycemia and many others. Again, 
a major goal of the UCTP is to discontinue steroid maintenance in all patients when 
possible, 
AGENTS USED FOR CHRONIC IMMUNOSUPPRESSION: (CvA. Azathioprine.) 
Cvclosoorine 
CyclosporineA(CyA) exerts Its immunosuppressive effect upon the cell-mediated 
Immune response, but Is not a cytotoxic agent such as azathioprlne. It preferentially aits 
to inhibit T-helper cell function, by inhibiting the activity of lnterleukln-2, and the 
proliferation of cytotoxic T cells. It has minimal Inhibitory activity upon B cells. 
Cyclosporine does not interfere with T-suppressor cells, an effect which Is thought to be a 
major mechanism for achieving a state of tolerance to the allograft. 
When using a radioimmunoassay for serum samples, { a s does the U C T P ) 
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therapeutic serum concentrations are generally considered to fall within the 2 0 0 - 3 0 0 
ng/ml r a n p immediately post-op for the heart transplant recipient, Serum 
concentrations are then tapered (depending on the program) to 1 0 0 - 2 0 0 ng/ml by the 
second or third month provided rejection is not recurring. 1 . 4 , 1 3 5 1 4 
Side effects secondary to cyclosporine are numerous. Nephrotoxicity, as 
manifested by elevated blood urea nitrogen, creatinine and electrolyte abnormalities 
(hyperkalemia) are common. CyA nephrotoxicity In the renal transplant recipient has 
been defined as a greater than 2 5 1 Increase in serum creatinine (SCr) over a several day 
period which Is reversible by a dose reduction. 15 
Cardiovascular disorders in the form of hypertension may occur, The heart 
transplant recipient appears to have the highest Incidence of hypertension among CyA 
treated patients. Hypertension secondary to CyA mer/ be a manifestation of stimulation of 
the renin-angiotensin system and Increased plasma renin a c t i v i t y . 1 6 
Hepatotoxicity (Increased total and direct bilirubin) can occur In about 50 
percent of patients, and hematological side effects such as mild thrombocytopenia and 
leukopenia have been reported secondary to cyclosporine therapy. Elevated blood glucose 
has been reported as well as hyperuricemia and hypercholesterolemia, A relationship 
between serum cyclosporine concentrations (Cp) and some of these effects (elevated 
serum creatinine, Increased bilirubin) has been established. 
Azsthioprine 
A28thioprine has been one of the primary immunosuppressive agents for 
transplant recipients. It is a cytotoxic agent (antimetabolite) which Is metabolized in 
vfvo  to 6 - mercaptopurlne. DNA synthesis and subsequent B - or T - lymphocyte 
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proliferation is inhibited by the agent. Azathioprine is not specific for lymphocytes 
however, and will inhibit all rapidly dividing cells to some degree. Therefore, bone 
marrow suppression Is a common side effect. 8 A target total white blood cell count of 
approximately 6 . 0 0 0 / m m 3 is a desired endooint for AZA therapy in the cardiac 
transplant recipient. 
ENDOMYOCARDIAL BIOPSY 
In order to monitor the patient for acute rejection, endomyocardial biopsy ( B x ) is 
performed routinely. The UCTP uses a light microscopic scoring system to measure 
rejection based on five categories: Grade 1 - no evidence for rejection, Grate 2 - cannot 
rule out mild, Grade 3 - mild, Grade 4 - moderate rejection and Grate 5 - severe rejection. 
The grades are differentiated based upon the degree of lymphocyte infiltration and 
presence of necrosis. 6 Biopsies are performed routinely every week for the first 6 - 8 
weeks at which time the Bx frequency is adjusted according to trends in results. 4 
Therapy for rejection was followed as outlined in Appendix I. 
Finally, as with most patients receiving Immunosuppressants, this population is 
more prone to infectious complications (bacterial, viral , fungal), Infection appears to be 
the leading cause of mortality for the cardiac transplant patient, 1 7 
O b j e c t i v e ? 
The purpose of this project was to describe the various regimens used by the Utah 
Cardiac Transplant Program and the graft survival and adverse effects of each of the 
different regimens, Specifically the following data were collected and examined, 
10 
1 .) The average biopsy score and incidence of rejection in relationship to the 
regimen used, doses of immunosuppressants and serum concentrations of CyA 
when available. 
2 . ) The acute and chronic adverse effects of cyclosporine, chronic defined as 
therapy of greater than three months duration. 
3 .) The relationship of the side effects in * 2 to observed serum concentrations 
and doses of CyA. 
4 . ) Acute and chronic effects of other immunosuppressive agents. 
5.) Changes in the total white blood cell count and lymphocyte count and any 
relationship to acute rejection episodes, 
6.5 Types and occurrence of infection in patient groups, 
Methods 
This study was conducted In a retrospective manner by reviewing the charts of the 
first 50 cardiac transplant patients cared for by the UCTP. Data collection continued on 
all patients through December 1 , 1986, Patients undergoing transplant surgery through 
September 1986 were included. Data collection for this study was performed dally for the 
first 14 days post-transplant, then three times weekly as available until week 4, After 
this time, data collection was dependent upon the regularity of follow up. Patient charts 
were reviewed for a minimum time period of 3 months post transplant to a maximum of 
21 months, depending upon the regularity of follow up with laboratory assessment 
( S M A - 7 , CyA serum concentrations, B x , etc.). 
Fifty patients were included in the final analysis, A total of 129 inpatient 
hospital chart volumes were reviewed plus numerous clinic notes and medication charts, 
Only three chart volumes were not available. Informed consent from the patient was not 
required. Permission for chart review was granted by Michael Bristow, M.D. , Ph.D., 
Research Director of the UCTP. 
Conversion of intravenous to oral CyA was calculated using an oral bioavailability 
factor of 3 5 $ . 5 For the purposes of comparison, any dose of cyclophosphamide was 
converted to an equivalent of azathioprine using Img cyclophosphamide = 2mg AZA. 
Baseline data values were considered at the point post-op when the parameter had reached 
a stabilized value, 
Once enteral into one of the three protocols as indicated in Appendix I, patients 
remained 1n those protocols for the purposes of data analysis. Therefore, patients who 
received 0KT3 on a compassionate use basis did riot automatically move Into protocol 3 
since by definition protocol 3 was an early prophylaxis trial. 
Data Analysis 
Spearman correlation coefficients were calculated to determine if cyclosporine 
dose and or serum concentration had any linear correlation with the adverse or 
therapeutic effects that were monitored for in this study. The data from post-op week 2 
were chosen to perform the correlations since CyA Cp would have reached steady-state 
concentrations, and more accurate trough serum concentration measurements were 
available since patients were still hospitalized at this point, Simple linear regression of 
CyA Cp vs. CyA dose was also done to determine any relationship, To account for 
differences in dose of CyA and AZA (since they were Initially dosed upon a mg/kg basis) 
body surface area ( B S A - m 2 ) was also compared among groups, 
A comparison in all 50 patients of the rejecting heart (Bx > 3) versus the 
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non-rejecting heart (Bx score 1 and 2) was done In order to determine if any of the 
measured parameters were statistically significantly different in these two situations, i.e. 
possible predictors of rejection. Although somewhat equivocal in nature, a biopsy score of 
2 (cannot rule out mild rejection) was included In the non-rejecting state since this score 
did not mean automatic therapy for rejection as would a Grade 3 biopsy score. 
The Student's t-test for Independent samples was used and p values at the level of 
< 0,05 were considered statistically significant, using Statworks® (Cricket Software®, 
Philadelphia, Pa,) statistical program for the Macintosh Plus® computer. Comparisons 
were then done between the three protocols, 0KT3 recipients, vincristine recipients, and 
steroid maintenance patients in both the rejecting and non-rejecting states. However, the 
non-rejecting state was chosen as representative of the patients' chronic condition, 
Chi-square square analysis was done to determine if any statistical difference in 
steroid sparing effect was offered by the use of 0KT3 or vincristine. 
Linear plots of various parameters were performed on the group as a whole (i.e, 
serum CyA concentration and Bx results vs, time) to observe any general pattern of change 
over time, Data points shown in the figures are those of average weekly values for the 
stated parameter. 
Results 
Results are presented in order of the goals and objectives of the project for the 
following groups: 
1 . ) All patients. 
2 , ) Patients In Protocols 1 - 3 (designated as P 1 , P2 and P3). 
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3 . ) 0KT3 and non 0KT3 recipients (designated as GKT3+ and0KT3-), 
4 . ) Vincristine and non vincristine recipients (designated as VCR + and VCR-) , 
5.)Patients on corticosteroid maintenance and patients not receiving chronic 
corticosteroid therapy (designated as STER+ and S T E R - ) . 
PATIENT DEMOGRAPHICS 
Of the 50 patients reviewed, there were 44 males and 6 females. Ages ranged 
from 16 to 63 with an average age of 4 4 . 8 years. Two patients required repeat transplant 
operations and two patients died during the follow-up period. Excluding the two patients 
requiring repeat operations, twenty-five patients (5258) carried a pre-operative 
diagnosis of idiopathic dilated cardiomyopathy (predominantly in patients under 50 years 
of age), nineteen (40£)had diffuse coronary artery disease, (predominantly in patients 
over 50 years of age), two patients had valvular heart disease (45S), and one patient each 
had hypertrophic cardiomyopathy, and acute myocarditis. A total of seven patients 
required the use of 0KT3 under a compassionate plea graft salvage protocol; three in 
protocol 1 , and two each In protocols 2 and 3, 
COMPARISON OF THE REJECTING AND NON-REJECTING HEART 
When all 50 patients were compared for changes which may have occurred during 
rejection, only serum glucose was found to be significantly different from the 
non-rejecting state (table 1), 
BIOPSY SCORE RESULTS 
Results for all patients show an increasing trend fn Bx score before week 5 , and 
again around week 13. After week 1 3 , Bx score tended to gradually decrease through the 
end of follow-up (fig. 1). A linear correlation between CyA dose and/ or Cp with Bx score 
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did riot reach statistical significance (CyA dose r= 0.082, CyA Cp r= 0 . 0 2 7 ) . 
As shown in table 2 , average Bx score was not statistically different between any 
of the protocol groups, nor was the average time to the highest Incidence of rejection. 
Patients in P3 (0KT3 early prophylaxis) had significantly fewer rejection episodes per 
patient than did P1 or P2 patients. Only protocols 2 and 3 were statistically different in 
terms of time of follow-up, 
0KT3+ and 0KT3- patients also had no statistical difference in average Bx score, 
weeks of follow-up, or time to highest incidence of rejection, The number of rejection 
episodes per patient was lower In the 0KT3+ group however (table 3), Six of 16 ( 3 8 1 ) 
patients who received early prophylaxis with 0KT3 went on to require chronic 
corticosteroid maintenance Immunosuppression compared with 18 of 34 patients ( 5 3 1 ) 
who received standard ATO prophylaxis (p > 0.05, table 10). 
VCR+ and VCR- patients demonstrated no differences in average Bx score during 
rejection, but the time to the highest incidence of rejection showed a trend towards later 
rejection in the VCR+ patients (table 4). A total of 1 7 of 26 ( 6 5 1 ) VCR recipients did 
not require chronic steroid immunosuppression, while 9 of 24 ( 3 8 1 ) patients who did 
not receive VCR, required maintenance steroids (p > 0.05, table 1 1 ) . 
Table 5 shows that STER+ and S T E R - average Bx score were also not statistically 
significantly different but the number of rejection episodes per patient was higher In the 
STER+ group (by definition). Twenty-four patients ( 4 8 1 ) were categorized as chronic 
steroid maintenance patients ( S T E R + ) . 
CYC-OSPORINE DOSE AND SERUM CONCENTRATION 
Average cyclosporine doses for all patients showed an initial decrease until 
post-operative week 5, when a gradual increase toward baseline occurred. CyA Cp also 
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decreased in the initial post-operative period, followed by stable levels from weeks 5 - 1 2 , 
After week 1 2 , serum concentrations had decreased by 30% from baseline by the end of 
follow-up. For the entire patient group a poor linear relationship between cyclosporlne 
dose and serum concentration was demonstrated durlng baseline ( r = 0 . 4 1 0 , fig. 2). 
Between the protocols only P1 and P2 had a significant difference in BSA. In the 
non-rejecting state P1 and P 2 , and P1 and P3 had significant differences in CyA dose, but 
CyA Cp was statistically different among P1 and P2 only (table 6). Although CyA Cp's 
were higher in the non-rejecting state, these differences were not statistically 
significant CyA doses were significantly different between all of the protocols during 
rejection, but differences In serum concentrations did not reach statistical significance 
between any protocol groups (table 2). 
Both 0KT3+/ 0 K T 3 - and VCR+/ VCR- patients demonstrated significant 
differences In CyA dose, but not In Cp during periods of no rejection (tables 7 , 8). These 
relationships also held true during rejection episodes (tables 3 , 4 ) . In the STER+ group, 
CyA dose and Cp were not statistically different from S T E R - patients' while not rejecting 
(table 9). STER+ patients had significantly higher Cp's during rejection than S T E R -
patients although both groups had the same CyA dose (table 5). BSA was not significantly 
different between any of these groups. 
CYCLOSPORINE EFFECTS- RELATIONSHIP TO CYA SERUM CONCENTRATION AND AVERAGE 
DAILY DQ$E 
A. Renal (serum creatinine. 24 hour creatinine clearances, serum K - 0 
1. Serum creatinine and 2 4 hour creatinine clearance 
Results for all patients showed an initial post-operative decrease in SCr through 
16 
week 3 followed by a gradual Increase In SCr over time through week 24. SCr at the end 
of follow-up was approximately 2 0 1 higher than baseline (fig 3). Measured 24 hour 
creatinine clearance decreased only by about 1 0 1 during this period. There was a poor 
correlation between CyA Cp and dose and SCr ( r = 0 . 2 6 2 , 0 . 0 1 0 respectively). 
Within the limitations of the assay for serum creatinine, there were no 
statistically significant difference between any of the compared groups during no rejection 
or during rejection episodes (tables 2 - 9 ) , 
11, Serum potassium 
Results for all patients showed an initial increase in serum K+ through week 2 , 
followed by a gradual Increase to approximately 0.1mEq/l over baseline by the end of 
follow-up, Serum potassium remained at approximately 4,5 mEq/1 throughout 
follow-up. Serum K+ did not correlate with either CyA dose ( r = 0 , 1 3 2 ) or CyA Cp ( r = 
0.218). 
No significant differences in serum K+ were found for any groups In the 
non-rejecting state (tables 6 - 9 ) , Patients in P 3 had higher serum K+ during rejection 
episodes, compared to P1 and P 2 , but this difference did not reach statistical significance, 
nor were these values considered to be hyperkalemic (table 2). 0KT3 patients also had 
higher serum K+ during rejection episodes, but the differences were not statistically 
significant (table 3). Both Y C R + / VCR- and S T E R + / S TER - patients had no difference 
between serum potassium concentrations during rejection episodes (tables 4 , 5 ) , 
B. Cardiovascular (systolic and diastolic blood pressure) 
In reviewing all 50 patients, systolic blood pressure ( S B P ) , although showing 
considerable variation over time, typically remained 1n the 1 2 0 - 1 5 0 mm Hg range 
throughout fallow-up. Diastolic blood pressure ( D B P ) had a steady upward climb which 
started at post-operative week 1 and eventually had increased by approximately 1 0 1 
over baseline by week 24. This occurred in the presence of more Intense 
antihypertensive therapy (fig. 4). Poor correlations between CyA dose ( r = 0 . 1 2 9 , 0.025 
for SBP and DBP, respectively), CyA Cp ( r = 0 . 1 0 6 , 0.075 for SBP and D B P , 
respectively) and blood pressures were found during the baseline period. 
In the non-rejecting patient, the only difference found was a higher SBP in STER+ 
compared to S T E R - patients (table 9). When all other comparisons are taken Into 
account, SBP and DBP did not differ significantly between any of the protocols or between 
0KT3+/ 0 K T 3 - , VCR+/ V C R - , and STER+ / S T E R - patient groups (tables 2 - 8 ) . 
C. Endocrine (serum glucose, serum cholesterol) 
i. Serum glucose 
For all patients, fasting serum glucose concentrations decreased slightly from a 
mildly hyperglycemic baseline to the high normal range ( 1 2 0 mg/dl) by the end of 
follow-up (fig, 5). At baseline, a poor correlation was found between CyA Cp ( r = 
0 , 3 1 8 ) , CyA dose ( r = 0 . 1 2 5 ) and serum glucose, 
In non-rejecting patients serum glucose was significantly different between P I 
and P3 only. In the rejecting state serum glucose was significantly higher for P1 patients 
as compared to P2 and P3 (tables 2 , 6), 0 K T 3 - patients had significantly higher serum 
glucose values than 0KT3- patients in non-rejecting periods, while no significant 
difference was seen between 0KT3+ and 0 K T 3 - patients during rejection episodes (tables 
3 , 7) . VCR patients had no difference 1n glucose when patients were not rejecting, but 
VCR+ patients did have higher fasting glucose than VCR- patients during rejection 
18 
episodes (tables 4 , 8), When comparing STER+ and STER- patients, the STER+ patients 
showed a trend towards higher glucose at all times but the difference was only statistically 
significant during rejection episodes (tables 5, 9). 
A total of four STER+ and one S T E R - patient ( 1 0 1 ) required glucose lowering 
agents during the first six months post-op (three- insulin, two- oral agents), 
11 Serum cholesterol 
Considering all patients, the average serum cholesterol was less than 150 mg/dl 
at week 1 , but by week 5 It was consistently above 200 mg/dl. After week 10, It slowly 
increased to the 2 2 0 - 2 5 0 mg/dl range by the end of follow-up (fig. 6). A poor 
correlation was found for CyA dose ( r = 0 . 3 4 1 ) , CyA Cp ( r = 0 , 1 8 3 ) and serum 
cholesterol during the baseline period, 
During periods of no rejection, only P I and P3 demonstrated a significant 
difference in serum cholesterol compared to each other. During rejection episodes there 
was no significant difference in serum cholesterol between any of the protocols (tables 2 , 
6). However, 0KT3+ patients did have significantly lower serum cholesterol than 0 K T 3 -
patients in both comparisons (tables 3, 7) , VCR+/ VCR- patients had no significant 
differences in serum cholesterol at any point (tables 4 , 8 ) , STER+, compared to S T E R -
patients, had significantly higher cholesterol values in the non-rejecting periods, but no 
significant differences were seen during rejection episodes (tables 5 , 9 ) . 
AZATHIOPRINE EFFECTS 
The average AZA dose for all patients decreased substantially through week 20 at 
which time it rose again to near baseline values (fig. 7 ) , AZA dose and Bx score did not 
correlate well ( r = - 0 , 0 5 5 ) . 
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When comparing A2A dose between the protocols, P3 had the highest average dose 
and all three protocols had statistically different AZA doses in both non-rejecting and 
rejecting states (tables 2 , 6). 0KT3+ and VCR- patients also had significantly higher 
AZA doses than 0 K T 3 - and VCR+ patients, respectively In both non-rejecting and 
rejecting states (tables 3 - 4 , 7 - 8 ) , Only S T E R + / S T E R - patients had the same AZA dose 
In both non-rejecting and rejecting states (tables 5 , 9), 
A total of eight patients received at least a brief course of cyclophosphamide 
therapy postoperatively, two due to documented AZA induced pancreatitis as diagnosed by 
elevated serum amylase and clinical findings. Symptoms resolved spontaneously in both 
patients after AZA therapy was discontinued. A positive rechallenge was obtained in one 
patient. One patient received cyclophosphamide immediately post-operatively (a repeat 
transplant), while the other patients changed therapy from 4 - 1 2 weeks post-op. A single 
patient received weekly methotrexate at one point for possible chronic rejection vs CyA 
induced myocardial fibrosis, 
VINCRISTINE EFFECT? 
As indicated previously, a total of nine of twenty-six patients ( 3 4 1 ) who 
received VCR and fifteen of twenty-four patients ( 6 3 1 ) who did not receive VCR went on 
to require chronic corticosteroid maintenance immunosuppressive (p > 0 , 0 5 , table 1 1 ) . 
Many patients who received VCR experienced at least mild signs and symptoms of 
vincristine toxicity. Thirteen of twenty-six patients ( 5 0 1 ) had findings consistent with 
peripheral neuropathy, Side effects were severe enough to require a dose reduction or 
temporary cessation of VCR therapy in four patients ( 1 5 1 ) . Two patients were 
hospitalized for treatment of paralytic ileus and seven patients ( 2 7 1 ) complained of 
significant constipation which was managed with stool softeners and bulk laxatives. Only 
three patients ( 1 2 $ ) had a significant degree of alopecia. A total of three patients 
( 1 3 £ ) who did not receive VCR had signs and symptoms of peripheral neuropathy, 
WHITE C E L L CHANGES AND RELATIONSHIP TO BIOPSY SCORES (total WBC. lymphocyte 
count) 
A. Total WBC 
For all patients WBC count decreased by one-half of the baseline value to 
approximately 6 , 0 0 0 m m 3 by the end of follow-up (fig. 8). WBC count showed poor 
correlation with Bx score ( r = - 0 . 1 4 5 ) . CyA dose ( r = 0.026) and Cp ( r = 0.020) also 
showed poor correlation with WBC count, AZA dose and total WBC count showed a weak 
negative correlation ( r = - 0 . 4 2 7 ) , 
VCR+ recipients showed a trend towards lower WBC count during the 
non-rejecting periods only (table 8). In all other comparisons WBC count was not 
statistically different between any of the three protocol groups, nor 0KT3+/ 0 K T 3 - , and 
STER + / S T E R - (tables2 - 7 , 9 ) , 
B, Lymphocyte count 
For all patients the number of lymphocytes increased from approximately 10 to 
2 0 f by week 24 (fig, 9), Lymphocyte count and Bx score did not correlate ( r = 0.087) . 
Neither AZA dose ( r = 0.093) , CyA dose ( r = 0 , 2 0 9 ) nor Cp ( r = 0.363) correlated with 
lymphocyte count. 
Patients in P 3 had the highest lymphocyte count during both periods, and were 
significantly different from both P i and P2 patients (tables 2 , 8). 0KT3+ patients also 
had significantly higher lymphocyte counts during both non-rejecting and rejecting 
periods than 0 K T 3 - patients (tables 3 , 7 ) . VCR+ patients had higher lymphocyte counts 
In the non-rejecting state while VCR+/ VCR- were the same during rejection episodes 
(tables 4 , 8). S T E R - patients also had higher lymphocyte counts during non-rejecting 
periods while S T E R + / S T E R - were the same during rejection (tables 5 , 9 ) , 
INFECTIONS 
Data on types of infections and causative organisms are presented in table 12. 
Protocol 2 patients receiving steroid maintenance therapy had the greatest number of 
infections, although this was not statistically significant. All patients were given 
prophylactic oral nystatin and/or clotrimazole plus oral acyclovir while on high doses of 
steroids. 
The most common bacterial pathogen was S  epidermfdis,  followed closely by £ 
co/i The most common viral infection was herpes simplex I, A total of 16 cases of herpes 
were seen along with 11 cases of "herpetic lesions," mainly on the nose and lips. 
Systemic fungal infections were not encountered in any patients; only mild oral 
and cutaneous types were documented. Three cases of Pneumocystis pneumonia occured, 
all irt Protocol 3 patients, Twelve patients seroconverted from cytomegalovirus (CMV) 
negative to positive during the follow up period. One patient acquired a CMV pneumonia 
which was successfully treated with 9 - ( 1,3-d1hydroxy-2-propoxymethyl)guan1ne 
( D H P G , ganciclovir). 
The Incidence of infection In our patient sample was (expressed in terms of total 
follow up period) 1.4 bacterial infections, 0.5 viral infections (Including CMV positive 
urine cultures which were not treated), 0,1 fungal Infections and 0.06 protozoal 
infections per patient. In terms of incidence relating to site; 2 8 1 were pulmonary, 2 3 1 
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urinary tract, 1 8 1 wound, 1 3 t blood, 1 2 8 oral (oral Candida and herpes virus) and 
6 $ other 
Focusing on CMY, of 23 patients who were seropositive at transplant, five ( 2 1 SB) 
went on to develop CMV infections (positive cultures), none of which required treatment, 
All 13 patients who remained seronegative throughout follow-up remained free of 
Infection. Nine patients seroconverted post-operatlvely ( 1 8 1 ) , and of these, three 
developed infections- two of which were pneumonias. This results In a 1 4 $ Incidence of 
infection among all initially seronegative patients. The two patients who developed CMV 
pneumonia did so on weeks 13 and 1 5 , and both converted from seronegative to positive, 
One of these patients also developed concomitant Pneumocystis pneumonia. 
Discussion 
COMPARISON OF THE NON-REJECTING AND REJECTING HEART 
Since only serum glucose was found to be significantly different between the 
non-rejecting and rejecting states this again emphasizes that blood chemistry 
determinations are of little value In evaluating a patient for rejection, Endomyocardial 
biopsy still remains the standard by which other methods of evaluation are compared. 
Actually, one may easily explain an elevated serum glucose In a rejection setting since It 
is probably a result of the effect of increasing doses of corticosteroids. 
BIOPSY SCORE 
When the various protocols of the UCTP are compared it becomes apparent that the 
addition of 0KT3 to the regimen reduced the Incidence of early rejection versus ATG. 
Although average Bx scores were not statistically different between those patients 
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randomized to 0KT3 versus AT6, the clear decrease in incidence of rejection per patient 
will likely have a favorable Impact upon long term survival. 
For the entire patient sample, cyclosporine serum concentrations and dose did not 
correlate to Bx score. This is also supported by data from Burstaln et a l 5 who failed to 
demonstrate any relationship between total dally dose of CyA and average trough serum 
concentration In predicting rejection episodes and recommended monitoring CyA Cp only to 
avoid toxicity. 
Azathioprine dose alone also failed to show any correlation with Bx score, These 
findings are consistent with the data in table 1 , which indicates no statistical difference 
between doses of immunosuppressants in non-rejecting versus rejecting periods, i.e. 
rejection is dependent upon multiple M o r s and not the disposition of only one agent. 
Data from VCR randomized patients showed two favorable effects. First, a trend 
towards a decrease in early rejection ( p « 0 . 0 8 9 ) and second, a steroid sparing effect by 
having fewer patients who eventually required chronic steroid maintenance therapy In the 
VCR+ group. Both of these findings may reach statistical significance with a larger 
sample size, 
The significant number of patients who did not require chronic steroid 
maintenance therapy allowed the first opportunity to compare the effects of long term 
corticosteroid use In these patients, Since average Bx score was not statistically different 
between steroid subgroups, this demonstrates that the cardiac transplant recipient can, in 
many instances, be taken off chronic steroid maintenance therapy, thereby avoiding the 
numerous adverse effects of corticosteroids, 
CYCLOSPORINE DOSE AND SERUM CONCENTRATION 
Several potential problems were avoided by using the data from the second week 
post-op when considering the relationship between CyA and other variables. More 
accurate trough concentrations at steady state were obtainable and problems of outpatient 
compliance were avoided. 
The logarithm of CyA serum concentration correlated poorly with CyA dose as 
previously Indicated, This finding may have been due In part to the retrospective nature 
of the study. The available pharmacokinetics studies 1 8 1 1 9 have demonstrated a 
linear relationship between dose and Cp, These studies have shown an increasing Cp with 
decreasing dose over time. 1 6 > 1 8 > 2 0 This is thought to be due to either a 
"saturation" phenomenon of a central bat/ compartment or an Increase In bioavailability 
over time. This phenomenon was not clearly seen In our patient sample over a 24 week 
period. 
Several Individual cases of non-linear changes in dose and serum concentration 
were encountered during follow-up and attributed to the possibility of drug Interactions. 
As an example, some of our first patients received calcium channel blockers as a routine 
part of their antihypertensive therapy. Subsequently a report of an increase in serum 
concentration of CyA secondary to a diltlazem - CyA interaction has been documented. 2 1 
Kahan et al, found an elevation In OyA Cp In patients receiving a slow steroid taper prior 
to total discontinuation of s t e r o i d s . 2 2 Other reported drug interactions with cyclosporine 
include: dmetidlne, high dose corticosteroids, ketocona2ole, and erythromycin (Increased 
CyA serum concentrations), Decreased CyA serum concentrations have been demonstrated 
with rifampin, phenytoin, phenobarbital and antlstaphylococcal penicillins 2 3 As with 
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any agent, as more experience is gained, a larger number of drug Interactions will be 
discovered. 
Although early prophylaxis with 0KT3 decreased rejection incidence, CyA dose 
was significantly higher in 0KT3 recipients, This effect is almost certainly not secondary 
to a drug interaction between CyA and 0KT3 since the later is given for only a two week 
course. It is also not explained by a difference in patient weight since BSA and serum 
concentrations were not different. One possible explanation could be the larger number of 
patients on chronic steroids In the 0KT3- group, skewing the Cp's upward without a 
larger dose. 
The higher CyA doses in VCR- patients is not readily explained since Cp's were the 
same between the two groups and more patients were actually STER+ in the VCR- group. 
Again, this effect is almost certainly not secondary to a drug interaction between CyA and 
VCR since the later Is given only weekly for eight doses. The higher CyA serum 
concentrations In STER+ patients in view of equal CyA dose may also represent the above 
CyA-corticosteroid Interaction. Body surface area was not different between any of these 
groups so the difference cannot be explained by a difference in patient weight (BSA). 
CYCLOSPORINE SIDE EFFECTS - RELATIONSHIP TO SERUM CONCENTRATION A N D DOSE 
Although the side effect profile of CyA is well known, relatively little data exists 
regarding any relationship between dose and serum concentrations and adverse effects 
upon various organ systems. 
Elevations in serum creatinine with concomitant Increases In serum 
concentrations of CyA have been documented In several reports.1®* 2 4 , 2 5 , 26 Although 
the exact mechanism of CyA nephrotoxicity Is not known, one theory centers around acute 
in,.. 
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changes In renal hemodynamics secondary to renal vasoconstriction which leads to tubular 
damage. A direct nephrotoxic reaction has also been proposed. 1 8 
Since CyA Cp and tee both showed poor correlation to changes In SCr In these data 
( r = 0 . 2 6 2 , 0 . 0 1 0 ) it suggests that CyA nephrotoxicity may not be strictly dose related 
and that SCr must be monitored periodically, These data showed that SCr gradually 
increased by week 24 although patients had grossly norma! renal function as measured by 
24 hour urine collections for creatinine clearance. 
Several studies from renal transplant recipients 2 7 » 2 8 found patients on CyA 
maintenance therapy versus AZA controls were more likely to have higher serum K+ 
concentrations (> 5 mEq/1). The authors postulated that cyclosporine altered tubular 
function, and caused increased sodium reabsorption and decreased potassium secretion, 
While some patients had overt hyperchloremic metabolic acidosis, others were 
hyperkalemic without other electrolyte abnormalities. 2 7 » 2 8 Hyperkalemia may have 
been an even greater concern In our patient sample since they were routinely talcing 
combinations of agents associated with elevation of serum potassium such as ACEI's 
(angiotensin converting enzyme Inhibitors) and potassium sparing diuretics. Although 
hyperkalemia secondary to ACEI therapy Is reported, Schuna 2 9 found no significant 
changes In serum K+ during a retrospective review of patients on ACEI's with or without 
potassium sparing diuretic therapy, 
CyA dose and Cp did not correlate with changes in serum K+ In our sample ( r = 
0 . 1 3 2 , 0 . 2 1 8 ) and our data did not show any clinically significant degree of 
hyperkalemia although patients routinely took agents that have been previously associated 
with elevations of serum K+. Therefore, the choice of antihypertensives for these patients 
2 7 
should not exclude ACEI's based upon these findings. 
Cyclosporlne has also been shown to cause hypertension, especially In the cardiac 
transplant population (vs. AZA controls). The resulting hypertension 1s often v e r y 
difficult to control. Although the precise mechanisms causing this effect remains unclear, 
several authors 3 0 have postulated that stimulation of the 
renin-angiotensin-aldosterone system may be partially responsible. Suggestions that 
plasma renin activity increases in the cyclosporlne treated patient may partially explain 
hypertension due to renal vasoconstriction,18 Stahl , et al demonstrated in a sample of 
renal transplant patients (trough CyA Cp of 3 4 0 - 4 1 0 ng/ml) an actual decrease in 
plasma renin activity, but the authors did not address hypertension in their patient 
sample.^? 
No good correlation between CyA dose and Cp and blood pressure was seen in our 
patients. However, patients on chronic steroid maintenance therapy did have higher SBP 
during periods of no rejection. This again emphasizes the undesirable effects of long term 
corticosteroids. Overall, blood pressure was controlled on various combinations of ACE1 's, 
diuretics ( K + and non K+ sparing), and adrenergic inhibitors (clonidine, atenolol, and 
labetalol) although DBP continued to increase over time in most patients, 
Glucocorticoids are known to cause elevated serum glucose, and recently, a 
relationship between cyclosporlne and elevated blood glucose has been described. Bending 
3 1 reported a case of a renal transplant recipient who developed overt diabetes requiring 
moderate doses of insulin for control of blood glucose. Although the patient was receiving 
concomitant steroid therapy, the diabetic condition gradually resolved over a several 
month period after CyA was discontinued. The patient was not rechallenged with CyA. This 
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Individual had high CyA serum concentrations (> SOOnmol/l) for a period of 2 months 
with coinciding toxicities of tremor, hirsutism, and elevated SCr, The authors cite 
experimental data which indicate that a possible dose-related beta cell toxicity of CyA was 
responsible, However, another report in a sample of renal transplant p a t i e n t s , 3 2 could 
not demonstrate any relationship between CyA and serum glucose elevations. These 
patients received CyA for a 3 month period before crossing over to AZA, Average mean 
trough values of CyA were 143ng/ml. Only a decreased area under the curve for the 
glucose tolerance test after discontinuation of CyA was observed and attributed to chronic 
steroid use. 
A weak correlation ( r = 0 , 3 1 8 ) between CyA Cp and serum glucose was found in 
our patients during baseline. Since STER+ patients also showed a trend towards higher 
serum glucose (p= 0 . 0 6 1 ) , hyperglycemia may be another reason for attempting to 
discontinue maintenance steroids although an additive diabetogenic effect between CyA and 
glucocorticoids has not previously been described. Again, a l a r p r sample size may show a 
statistical difference. 0KT3+ patients also demonstrated lower fasting glucose values 
during periods of no rejection. 
Accelerated coronary artery atherosclerotic disease is a major factor contributing 
to the failure rate of long term graft survival, Accelerated atherosclerosis may be due to 
Immunological Injury to graft endothelium secondary to chronic rejection, resulting In 
platelet activation and eventual plaque formation. 3 3 > I f this Is Indeed the case, there 
Is an obvious need to decrease the number of rejection episodes. 
Although therapy with antiplatelet agents (dipyridamole and warfarin) 
significantly decreased the incidence of graft atherosclerosis in previous studies at 
Stanford, simultaneous changes in the overall protocol did riot allow statistical 
significance to be determined. Intensive antiplatelet therapy has now been discontinued at 
S t a n f o r d . 3 4 
The risks of accelerated CAD are apparently not related to pre-transplant 
coronary disease state, but the development of graft atherosclerosis may be enhanced by 
hyperlipidemia in the recipient, Uretsky et al 3 5 although finding no correlation with 
serum cholesterol, d t e animal data which suggests that blood lipids play an important role 
in the development of graft atherosclerosis in the cardiac transplant recipient, Becker et 
al found a substantial increase In serum cholesterol in a sample of cardiac transplant 
recipients but the authors did not comment on CyA Influences In their findings, Harris 
observed a significant decrease in fasting serum cholesterol when CyA was discontinued, 
thus demonstrating an apparent cholesterol elevating effect of cyclosporlne, independent of 
corticosteroids. One possible reason why cholesterol has not been shown to be strongly 
associated with CAD in these patients is that their survival time was relatively limited in 
comparison to studies in non-transplant patients. It is the non-transplant patient in 
which the role of hyperlipidemia and CAD has been defined, 
Although CyA dose and serum cholesterol showed a weak correlation ( r = 0 , 3 4 1 ) , 
no relationship between serum cholesterol and CyA Cp was seen, High normal to mildly 
elevated serum cholesterol ( 1 9 0 - 2 3 0 mg/dl) was found In all patient groups, (which is 
actually elevated if one considers the average age of the patients), Statistically significant 
elevations in serum cholesterol were Men 1n 0 K T 3 - and STER+ (versus 0KT3+ and 
S T E R - patients). One of 19 evaluable patients demonstrated coronary vessel changes 
during routine nine month cardiac catheterization Indicating that by that point In time 
accelerated CAD was not a problem. If hypercholesterolemia does indeed predispose the 
Individual to accelerated graft atherosclerosis, then the beneficial effects of 0KT3 and 
discontinuing maintenance steroids could be substantial. 
AZATHIQPP1NE EFFECTS 
The correlation between AZA dose and WBC was expected although AZA dose alone 
did not correlate with Bx score. The side effects due to AZA were minimal to absent. 
Eight patients were switched from azathloprlne to cyclophosphamide maintenance 
therapy, and of these, two were due to probable AZA induced pancreatitis. However, 
pancreatitis appears to occur spontaneously in approximately 1 0 1 of cardiac transplant 
patients. Non drug induced pancreatitis was ruled out in only one patient based upon a 
positive rechallenge. The time to onset of pancreatitis symptoms In our patients was 
usually later than in the study by Sturdevant. 3 8 Typically, AZA induced pancreatitis 
occurs about 21 days after therapy is begun and is manifested by intense gastrointestinal 
distress (nausea, anorexia, etc.) and elevation of serum amylase. 3 8 Our patients usually 
experienced signs and symptoms around post-op weeks four and five. 
Another Important finding is that although AZA was used in combination with VCR 
in some patients, no clear increase In Incidence of leukopenia was noted. 
VINCRISTINE EFFECTS 
In larger patient samples VCR will probably demonstrate that It delays the onset 
of rejection as indicated by the trend found In our patient sample ( p = 0 . 0 8 9 ) . VCR also 
appears to have the beneficial effect of having fewer patients continuing on to treatment 
with chronic corticosteroids, although the difference was not statistically significant. 
Since vincristine has virtually no hematological side effects associated with it , and no 
clear statistical difference in WBC was observed between patient groups, VCR can be 
considered as a safe adjunctive agent by hematological considerations. 
Since the side effects in the VCR group were often quite significant, the VCR study 
has recently reduced the total number of doses from eight to six. Many patients 
experienced some degree of peripheral neuropathy (decreased Achilles reflex and 
paresthesias in fingers and toes) but the effects usually resolved with time. Although 
several patients who did not receive VCR had components of peripheral neuropathy, 
steroid myopathy could not be demonstrated. 
Corticosteroid myopathy was ruled out as the cause for general weakness in VCR 
recipients based upon the predominant incidence in females and different clinical findings 
of primary pelvic girdle muscle weakness in steroid myopathy versus paresthesias In VCR 
toxicity, 
Several patients did require hospitalization for treatment of paralytic Ileus 
secondary to VCR, and many patients receiving vincristine complained of some degree of 
constipation. The Incidence and severity of these side effects are in general agreement 
.with those reviewed by Rosenthal 9 which implies that the incidence of these adverse 
effects are not increased In our patient population. 
QKT? EFFECTS 
As discussed previously, the decreased fasting glucose and serum cholesterol as 
well as the decrease in Incidence of rejection and steroid maintenance therapy make 0KT3 
a very Important agent in early prophylaxis therapy. 
The side effects from 0KT3 did not appear to be extremely severe or difficult to 
manage with the current pre-treatment protocol [Appendix 1 ] , Two patients developed 
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pulmonary edema (one was euvolemic), and most had the febrile reaction and headache 
previously described. 1 0 No patients in this study demonstrated the recently reported 
meningitis type reaction in several renal transplant recipients consisting of fever, 
cephalgia, photophobia and pleocytosis of the cerebrospinal fluid without an infectious 
process, 
Even with retreatment, 0KT3 recipients did not appear to have an increased 
incidence of adverse effects or production of 0KT3 antibody and subsequent resistance, 
The two patients who were retreated with 0KT3 In protocol 3 did not appear to suffer 
Increased side effects and their rejection responded to usual doses of 0KT3, All of these 
findings Indicate that OKT3 is a safe and effective agent for the early prophylaxis of 
rejection, The only remaining question Is; will the incidence of graft failure increase 
secondary to antibody formation and drug resistance in patients that require retreatment? 
WHITE C E L L CHANGES AND RELATIONSHIP TO BIOPSY SCORES 
Since rejection is the end effect of the host immune system reacting against the 
graft, the microscopic findings are those of lymphocytic infiltration and cellular necrosis 
when severe rejection is occurring. This implies that lymphocytes are Intimately 
Involved In the rejection process, 
Observations that total WBC lacked a positive relationship with rejection Is 
important since this may mean that rejection occurs Independent of a significant 
leukocytosis, Where WBC did Increase with Bx score, the possibility of simultaneous 
corticosteroid Induced leukocytosis must be ruled out. This differentiation can be made by 
observing subpopulatlons of white cells since steroids typically cause a leukocytosis with 
increased polymorphonuclear cells and monocytes, and decreased numbers of eosinophils 
and lymphocytes. 4 1 
Although the numbers of lymphocytes showed no correlation with rejection it is 
v e r y Interesting to note that greater numbers were often found in the OKT3+ groups, the 
same groups with a lower Incidence of rejection. This is inconsistent with the findings on 
biopsy of lymphocytic infiltration and not readily explained. As expected, CyA did 
demonstrate a preferential effect In inhibiting lymphocytes (versus total WBC) as 
compared to AZA, 
INFECTION 
The incidence of infection in our patient sample was in agreement with findings 
from other centers in that bacterial Infections of pulmonary origin were the most common 
type. The greatest difference was seen In fungal and nocardial Infections. In a control 
group from Stanford (consisting of AZA, prednisone and AT6 treated patients versus 
cyclosporlne), a per patient infection rate of 2.5 bacterial, 1.3 viral , 1.1 fungal, 1.0 
nocardia, and 1.1 protozoal was observed over a 13 year follow up period in 227 
patients. 4 2 The 1 4 $ Incidence of CMV infection among all initially seronegative patients 
is also similar to a recent report which found similar rates of CMV infection In 
cyclosporlne treated patients, 1 2 $ In seronegative and 3 4 $ In seropositive p a t i e n t s . 4 3 
CMV Infections prior to the one year anniversary of transplant are thought to be primary 
infections in n a t u r e . 4 4 It would also appear from our data that patients who seroconvert 
after transplant may be at higher risk for development of serious CMV infections, 
Previous data from Stanford and other centers Indicates that numbers of 
Infections are not significantly different in the traditional A Z A - prednisone therapy 
versus CyA therapy but the types of Infecting organisms are different. Protozoal, nocardia 
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and CMV infections were more common in the traditional groups, whereas now bacterial 
and fungal infections d o m i n a t e . S i g n i f i c a n t findings from the UCTP include; no 
deaths secondary to Infection, no nocardia infections and no systemic fungal infections. 
These data Indicate an Incidence of infection which is predominantly bacterial In nature 
with only superficial viral and fungal Infections, These results may indeed be influenced 
by fewer patients on long term corticosteroids, 
C o n c l u s i o n 
The 9 7 1 one-year patient survival rate observed in this group represents the 
best in the country at the time of this review. Several reasons for this high sucess rate 
are apparent by observing the structure of the program. F i r s t , post-operative care is 
consolidated under a group of three cardiologists who follow the patients In all three 
participating hospitals thereby providing standardized care. This point cannot be over 
emphasized. 
Secondly, the currently used protocols are laid upon the foundation of all previous 
work In the field and as such, provide the most optimal care, innovations such as 0KT3, 
VCR and discontinuance of maintenance steroids have also Improved long term patient care. 
These results reflect other findings in the literature which have already been 
discussed. Before summarizing our findings, again it must be kept in mind that this was 
conducted as a retrospective analysis and therefore has some inherent e r r o r and 
disadvantages. Although sample size was small, It does represent a significant percentage 
of cardiac transplant recipients. 
1 . 0 K T 3 appears to be a powerful agent, capable of not only reversing severe 
p 
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• rejection, 1 0 but also preventing Its occurrence. When combined with appropriately 
j dosed cyclosporlne A , azathioprlne and corticosteroids the incidence of early rejection is 
• decreased. 
2. Vincristine may decrease the time to first rejection episode and also appears to 
I have a long term beneficial effect in that fewer patients receiving VCR progress to the 
point of requiring chronic steroid maintenance therapy. 
; 3. Although corticosteroids may be required for graft survival in some patients, 
1 a significant number of patients can discontinue long term use and thereby avoid the 
I 
j adverse effects seen here. 
4, Poor positive correlations "between CyA serum concentration and dose for Bx 
score, serum creatinine, serum potassium, blood pressures, total WBC and lymphocyte 
count were found. Weak positive correlations were found for serum cholesterol and 
serum glucose 
| 5. The concomitant use of CyA with ACEI's and K+ sparing diuretics was not 
] associated with cl inlcally significant hyperkalemia, 
| 6. Total WBC and lymphocyte count did not correlate with Bx score. 
} 7 . Lastly, the approximately 5 0 * of patients who did not require chronic steroid 
| maintenance therapy are probably responsible for the altered incidence and severity of 
\ 
infection seen In our sample. Notably absent were numerous fungal infections as 
! 
i compared to historic controls. 
j The Utah Program has proved that sucessful cardiac transplantation can be 
| accomplished in a newly founded center and performed in such a manner that justifies 
1 
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Table 1. Comparison of rejection and non-rejection biopsy scores for all patients. 
Rejecting Non-Rejecting 
(mean ± one standard deviation) 
No. of Bx scores > 3 2 2 5 NA 
Rejections per patient 4 . 5 NA 
Bx score 3.6 ± 0 . 6 NA 
CyA dose (mg) 3 8 6 +. 1 3 7 395 +. 1 4 7 
CyA serum concentration (ng/ml) 2 0 6 ± 1 2 4 221 ± 1 5 8 
AZA dose (mg) 1 2 6 ± 7 0 1 3 4 ± 6 9 
Serum potassium (mEq/1) 4 . 5 ± 0 . 5 4 . 5 ± 0 . 5 
Serum creatinine (mg/dl) 1 .1 ± 0 . 5 1 . 2 ± 0 . 4 
Systolic blood pressure (mm Hg) 1 2 7 + . 19 129 +. 1 7 
Diastolic blood pressure (mm Hg) 8 0 ± 1 3 8 2 ± 1 2 
Serum glucose (mg/dl) 1 3 4 + . 6 0 * 121 ± 4 7 
Serum cholesterol (mg/dl) 2 2 0 ± 53 2 1 1 ± 55 
White blood cell count ( x 1000)/rrim3 8 . 3 ± 3 . 9 8 . 5 ± 4 . 3 
Lymphocyte count ( x 1 0 0 0 ) / m m 3 1 6 ± 1 2 1 6 + . 1 2 
* p < 0 . 0 5 between groups 
3? 
Table 2, Comparison of all protocols during rejection episodes. 
(mean ± one standard deviation) 
n - 1? 14 19 
No. of Bx scores > 3 90 84 55 
Rejections per patient 5 , 3 * 6 , 0 - * 2.9 @ 
Bx score 3 , 6 1 + 0 .7 3,65 + . 0 . 7 3 . 5 2 + 0.6 
Weeks of follow-up 2 1 , 5 + 7 . 0 23.2 ± 2 . 9 * 19.8 ± 3 . 9 
Time to highest incidence 
of rejection (weeks) 8 . 9 ± 5 . 7 8 , 7 ± 5 . 6 9 . 8 ± 5 . 3 
Body surface area ( r n 2 ) 1.88 ± 0 . 2 * 2 . 1 4 +.0.4 1.93 + . 0 . 2 
CyA dose (mg) 3 4 0 ± 1 2 5 * 4 2 4 ± 1 3 7 4 0 0 ± 1 3 6 @ 
CyA serum concentration (ng/ml) 189 ± 1 2 3 221 ± 1 2 8 2 0 3 ± 1 1 6 
AZA dose (mg) 9 7 ± 5 7 * 1 3 3 ± 6 8 * 1 5 9 ± 7 5 @ 
Serum potassium (mEq/1) 4 ,4 ± 0 . 5 4.4 ± 0 . 4 4 . 6 ± 0 . 5 
Serum creatinine (mg/dl) 1.1 ± 0 . 6 1.1 ± 0 , 2 1.1 ± 0 . 3 
Systolic blood pressure (mm Hg) 1 2 7 ± 19 126 ± 20 131 ± 2 0 
Diastolic blood pressure (mm Hg) 8 0 ± 13 7 8 ± 13 8 4 ± 1 2 
Serum glucose (mg/dl) 148 ± 7 1 . 5 * 125 ± 43 1 2 0 ± 6 1 
Serum cholesterol (mg/dl) 226 ± 5 1 . 3 2 1 9 ± 5 5 2 1 2 ± 5 4 
White blood cell count ( x 1 0 0 0 ) / m m 3 8.9 ± 3 . 5 7 . 8 ± 3 . 3 7 , 7 ± 5 . 2 
Lymphocyte count ( x 1 0 0 0 ) / m m 3 1 2 + 7 H + 1 0 * 2 6 ± 1 7 @ 
* p < 0 . 0 5 between Protocols 1 & 2 
@ p < 0 . 0 5 between Protocols 1 & 3 
* p < 0 . 0 5 between Protocols 2 &3 
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Table 3, Comparison of 0KT3+ and 0KT3- patients during rejection episodes, 
n= 
No. of Bx scores > 3 
Rejections per patient 
B x score 
Weeks of follow-up 
Time to highest incidence 
of rejection (weeks) 
Body surface area ( m 2 ) 
CyA dose (mg) 
CyA serum concentration (ng/ml) 
AZA dose (mg) 
Serum potassium (mEq/1) 
Serum creatinine (mg/dl) 
Systolic blood pressure (mm Hg) 
Diastolic blood pressure (mm Hg) 
Serum glucose (mg/dl) 
Serum cholesterol (mg/dl) 
White blood cell count ( x 1 0 0 0 ) m m 3 
Lymphocyte count ( x l 0 0 0 ) / m m 3 
m i * Q K T 5 -




3,62 + 0.6 
2 2 . 0 + 5.3 
8.9 ± 5 , 6 
1.98 + 0.3 
3 7 5 ± 1 3 8 
2 0 4 ± 1 2 5 
1 1 5 ± 6 5 
4.4 ± 0 . 5 
1,1 ± 0 . 5 
1 2 7 ± 1 9 
7 9 ± 13 
1 3 5 ± 5 9 
2 2 5 ± 5 5 
8.3 ± 3 . 4 
13 + 9 
3.1 * 
3,53 ± 0 , 6 
2 1 . 7 ± 6 , 6 
9 . 7 ± 5 . 5 
1 .94 ± 0 . 2 
4 2 2 ± 1 2 8 * 
208 ±120 
161 ± 7 7 * 
4.6 ± 0 . 6 
1.2 ± 0 . 3 
132 ± 2 1 
84 + . 1 2 
123 ± 65 
188 ± 2 1 * 
7 , 9 ± 5 . 6 
26 +.18* 
* p < 0 . 0 5 between groups 
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Table 4. Comparison of VCR+ and VCR- patients during rejection episodes. 
s i i 
( m e a n ± one standard deviation) 
n= 26 24 
No. of Bx scores > 3 1 1 4 1 1 5 
Rejections per patient 4 . 4 4,8 
Bx score 3.65 ± 0 , 7 3.55 ± 0 . 7 
Weeks of follow-up 20.6 ± 6 2 2 . 2 + 4 
Time to highest Incidence 
of rejection (weeks) 9 , ? ± 5 . 7 8 . 4 ± 5 . 3 
Body surface area ( m 2 ) 1.95 ± 0 , 3 1.99 ± 0 . 2 
CyA dose (mg) 3 4 6 ± 1 2 8 * 4 2 4 ± 1 3 6 
CyA serum concentration (ng/ml) 2 1 4 ± 122 1 9 6 ± 125 
AZA dose (mg) 1 1 2 ± 7 4 * 1 3 8 ± 6 3 
Serum potassium (mEq/1) 4 . 4 ±. 0.5 4,5 ± 0 , 5 
Serum creatinine (mg/dl) 1 , 2 + . 0 . 6 1 ,1 ± 0 . 2 
Systolic blood pressure (mm Hg) 1 2 7 ± 2 0 1 2 8 ± 19 
Diastolic blood pressure (mm Hg) 81 ± 1 3 7 8 ± 13 
Serum glucose (mg/dl) 1 4 6 + . 7 1 * 1 2 3 ± 4 7 
Serum cholesterol (mg/dl) 230 ± 5 7 2 1 2 + . 4 8 
White blood cell count ( x 1 0 0 0 ) / m m 3 7 . 7 ± 3 , 5 8 . 7 ± 4 . 1 
Lymphocyte count ( x 1 0 0 0 ) / m m 3 1 6 + 1 2 1 6 ± 12 
* p < 0 . 0 5 between groups 
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Table 5. Comparison of STER+ and STER- patients during rejection episodes. 
5 T E R + S T E R -
(mean ± one standard deviation) 
n= 2 4 26 
No. of Bx scores > 3 161 68 
Rejections per patient 6 . 7 * 2.6 
Bx score 3 . 6 3 ± 0 , 7 3.54 ±. 0,6 
Weeks of follow-up 2 2 . 2 ± 3 . 8 20.5 ± 6 , 0 
Time to highest Incidence 
of rejection (weeks) 9.1 +.5.6 8.8 ± 5 . 4 
Body surface area ( m 2 ) 1.96 ± 0 . 2 1 . 9 7 ± 0 . 3 
CyA dose (mg) 381 ± 1 3 5 394 ± 1 4 3 
CyA serum concentration (ng/ml) 2 1 9 ± 1 3 0 * 168 ± 9 8 
AZA dose ( mg) 126 ± 7 3 122 ± 6 3 
Serum potassium (mEq/1) 4 . 4 ± 0 , 5 4.5 ± 0 , 4 
Serum creatinine (mg/dl) 1,1 ± 0 . 5 1 .2 ± 0 . 4 
Systolic blood pressure (mm Hg) 128 ± 2 0 1 2 6 ± 19 
Diastolic blood pressure (mm Hg) 7 9 ± 13 81 ± 1 3 
Serum glucose (mg/dl) 141 ± 6 2 * 1 1 4 ± 5 0 
Serum cholesterol (mg/dl) 2 2 4 ± 5 5 2 1 3 ± 4 8 
White blood cell count ( x 1 0 0 0 ) / m m 3 8.4 ± 4 . 1 7 , 7 ± 3 . 3 
Lymphocyte count ( x 1 0 0 0 ) / m m 3 15 ± 1 2 1 8 ± 13 
* p < 0.05 between groups 
f t 
Table 6. Comparison of all protocols during periods of no rejection. 
Protocol 1 Protocol 2 Protocol 3 
(mean ± one standard deviation) 
n= 1 7 1 4 19 
Weeks of follow-up 2 1 , 5 + . 7 2 3 . 2 ± 2 . 9 19,8 ± 3 , 9 
Body surface area ( m 2 ) 1 . 8 8 + 0 . 2 * 2 , 1 4 ± 0 , 4 1 .93 ± 0 . 2 
CyA dose (mg) 358 ± 1 1 6 * 4 2 7 ± 1 6 8 4 0 4 ± 1 4 8 « 
CyA serum concentration (ng/ml) 1 9 4 ± 1 2 7 * 2 5 6 ± 158 # 2 1 5 ± 1 7 4 
AZA dose (mg) 102 ± 4 6 * 1 3 8 + . 7 5 * 158 ± 7 0 @ 
Serum potassium (mEq/1) 4 . 4 ± 0 , 5 4 . 5 ± 0 . 6 4.5 ± 0 . 4 
Serum creatinine (mg/dl) 1 . 2 ± 0 . 4 1 ,2+_0.3 1.3 ± 0 . 4 
Systolic blood pressure (mm Hg) 130 ± 1 6 1 3 0 ± 19 1 2 8 ± 15 
Diastolic blood pressure (mm Hg) 8 2 ± 1 1 8 2 ± 13 8 2 ± 11 
Serum glucose (mg/dl) 130 ± 5 9 123 ± 40 1 1 4 ± 4 0 @ 
Serum cholesterol (mg/dl) 2 2 5 ± 4 8 2 1 0 ± 5 8 1 9 7 ± 5 7 @ 
White blood cell count ( x 1 0 0 0 ) / m m 3 8.9 ± 3 . 7 8 . 5 + 4 , 5 8 . 3 ± 4 . 6 
Lymphocyte count ( x 1 0 0 0 ) / m m 3 1 4 + 9 12 ± 1 0 * 2 0 i 14 # 
* p < 0 . 0 5 between Protocols 1 & 2 
* p < 0 . 0 5 between Protocols 1 & 3 
* p < 0 . 0 5 between Protocols 2 &3 
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Table 7 . Comparison ofOKT3+ andOKT3- patients during periods of no rejection. 
n= 
0 K T 3 ± 0 K T 5 -
(mean ± one standard deviation) 
16 34 
Weeks of follow-up 2 0 + . 4 . 2 22 ± 5 . 3 
Body surface area ( m 2 ) 1 .95 ± 0 . 2 1.99 ± 0 . 3 
CyA dose (mg) 4 2 1 ± 1 4 6 * 381 ± 1 4 6 
CyA serum concentration (ng/ml) 2 1 4 ± 1 8 4 2 2 5 ± 1 4 3 
AZA dose (mg) 1 5 6 ± 7 1 * ! 2 3 ± 6 4 
Serum potassium (mEq/1) 4 . 5 ± 0 . 4 4.4 ± 0 , 5 
Serum creatinine (mg/dl) 1 . 3 ± 0 . 4 1 . 2 + . 0 . 4 
Systolic blood pressure (mm Hg) 1 2 8 ± 14 130 ± 18 
Diastolic blood pressure (mm Hg) 8 2 ± 11 8 2 ± 12 
Serum glucose (mg/dl) 109 ± 3 7 * 128 ± 5 1 
Serum cholesterol (mg/dl) 193 ± 54 * 2 1 7 ± 5 5 
White blood cell count ( x 1 0 0 0 ) / m m 3 8.1 ± 4 , 5 8,8 ± 4 . 2 
Lymphocyte count ( x 1 0 0 0 ) / m m 3 2 1 ± 1 4 * 13 +_ 9 
* p < 0 . 0 5 between groups 
Table Comparison of R+ and R - patients during periods of no rejection. 
m*.  i £ B r 
( m e a n ± one standard deviation) 
n= 2 6 24 
Weeks of follow-up 2 0 . 6 ± 6 2 2 , 2 ± 4 
Body surface area ( m 2 ) 1 .95 ± 0 . 3 1.99 ± 0 . 2 
CyA dose (mg) 3 7 4 ± 1 5 4 * 4 1 6 ± 1 3 6 
CyA serum concentration (ng/ml) 2 2 8 ± 1 8 7 2 1 5 ± 1 2 8 
AZA dose (mg) 1 1 9 ± 7 2 * 1 5 0 ± 6 2 
Serum potassium (mEq/1) 4 . 4 ± 0 . 5 4.5 ± 0 , 5 
Serum creatinine (mg/dl) 1 . 3 ± 0 , 5 1.2 ± 0 . 3 
Systolic blood pressure (mm Hg) 1 2 8 ± 16 130 ± 18 
Diastolic blood pressure (mm Hg) 8 1 ± 1 1 83 J L 1 2 
Serum glucose (mg/dl) 1 2 5 ± 5 5 1 1 8 ± 3 7 
Serum cholesterol (mg/dl) 2 0 5 ± 5 7 2 1 6 ± 5 4 
White blood cell count (x 1 0 0 0 ) / m m 3 8 , 1 ± 4 . 3 * 9.0 ± 4 , 3 
Lymphocyte count ( x 1 0 0 0 ) / m m 3 1 8 ± 1 2 * 15 ± 12 
* p < 0 . 0 5 between groups 
Table Comparison of R+ and R - patients during periods of no rejection 
n= 
Weeks of follow-up 
Bod/ surface area ( m 2 ) 
CyA dose (mg) 
CyA serum concentration (ng/ml) 
A Z A dose (mg) 
V C R f VCR— 
(mean ± one standard deviation) 
2 6 24 
2 0 . 6 ± 6 2 2 , 2 + 4 
1 .95 ± 0 . 3 1.99 ± 0 . 2 
3 7 4 ± 1 5 4 * 416 ± 1 3 6 
2 2 8 ± 1 8 7 215+_ 1 2 8 
1 1 9 + 7 2 * 150 ± 6 2 
Serum potassium (mEq/1) 4 . 4 ± 0 . 5 4.5 ± 0 . 5 
Serum creatinine (mg/dl) 1 . 3 ± . 0 . 5 1 . 2 ± 0 , 3 
Systolic blood pressure (mm Hg) 1 2 8 ± . 1 6 130 ± 18 
Diastolic blood pressure (mm Hg) 81 ± 1 1 8 3 ± 12 
Serum glucose (mg/dl) 1 2 5 ± 5 5 118 ± 3 7 
Serum cholesterol (mg/dl) 2 0 5 ± 5 7 2 1 6 ± 5 4 
White blood cell count ( x 1 0 0 0 ) / m m 3 8.1 ± 4 , 3 * 9,0 ± 4 , 3 
Lymphocyte count ( x 1 0 0 0 ) / m m 3 1 8 ± 1 2 * 1 5 ± 1 2 
* p < 0 . 0 5 between groups 
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Table 9, Comparison of STER+ and S T E R - patients during periods of no rejection. 
S T E R * S T E R -
(mean ± one standard deviation) 
n= 2 4 26 
Weeks of follow-up 2 2 . 2 ± 3 . 8 2 0 . 5 ± 6 , 0 
Body surface area ( m 2 ) 1 .96 ± 0 . 2 1 . 9 7 ± 0 , 3 
CyA dose (mg) 3 9 6 ± 1 4 3 395 ± 1 5 0 
CyA serum concentration (ng/ml) 2 3 9 ± 1 4 5 * 206 ± 1 6 8 
AZA dose (mg) 1 3 8 ± 7 6 1 3 2 ± 6 2 
Serum potassium (mEq/1) 4 . 4 ± 0 . 5 4.5 ± 0 . 5 
Serum creatinine (mg/dl) 1 .1 ± 0 , 3 1.3 ± 0 . 4 
Systolic blood pressure (mm Hg) 131 ± 1 7 * 1 2 7 ± 16 
Diastolic blood pressure (mm Hg) 8 3 ± 12 81 ± 11 
Serum glucose (mg/dl) 1 2 6 ± 5 3 * 1 1 7 + 4 0 
Serum cholesterol (mg/dl) 2 1 9 ± 5 9 * 201 ± 5 0 
White blood cell count ( x 1 0 0 0 ) / m m 3 8.8 ± 4 . 1 8.3 ± 4 , 4 
Lymphocyte count ( x l 0 0 0 ) / m m 3 1 4 ± 1 1 * 18 JL 1 2 
* p < 0 . 0 5 between groups 
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Table 10. Chi- square analysis of 0KT3 steroid sparing effects. 
0 K T 3 + 0 K T 3 -
S T E R + 6 1 8 || 2 4 
S T E R - 1 6 || 2 6 
16 34 50 
(p > 0.05 between all groups) 
Table 1 1 . Chl-square analysis of V C R steroid sparing effects, 
V C R * V C R -
S T E R + 9 15 II 2 4 
S T E R - 1 2 a I' 
26 2 4 50 
(p > 0,05 between all groups) 
«t7 
Table 12. Infecting Organisms and Sites of Infection 
Causative Species MumBff Of W l S O f e 
S. epldermidls 1 5 
E. coll 1 1 
S. aureus 9 
S. pneumonia 9 
Serratiasp. 4 
K. pneumonia 4 
P. aeruginosa 2 
Gardnerella vaginalis 2 
H. Influenza 2 
Diptheroides 2 
Legionella pneumonia 2 
Enterobacter sp. 2 
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A P P E N D I X 1 
STANDARD IMMUNOSUPPRESSANT PROTOCOL: ( 4 / 8 5 ) 
Pre-Op: D A Y O 
( 1 . ) CyA 3 mg/kg I.V, over 4 - 6 hr. (Give 2.5 mg/kg If creatinine clearance is < 25 
ml/min. or bilirubin > 2 mg/dl), Pre-treat with diphenhydramine 50mg I.V. and 
hydrocortisone 10Omg I.V. 
( 2 . ) AT6AM® 10 mg/kg I.V. over 4 - 6 hr. Pre-treat as with I.V. CyA plus acetaminophen 
650mg P.O. 
( 3 . ) Azathioprlne 4 mg/kg I.V, over 1 hr, 
Intra-Op: ( 1 . ) Methylprednisolone 500mg I.V. x 1 dose. 
POSt-Qp: DAY 1 
( 1 . ) Methylprednisolone 125mg I.V. q 8 hr. x 3 doses, 
( 2 . ) ATGAM® 10 mg/kg/day over 4 - 6 hr. x 7 days. Pre-treat as with I.V. CyA. Follow E, 
rosettes, target for < 1 0 $ . 
( 3 , ) Azathioprlne 2 mg/kg I.V. or P.O, q day. Decrease dose for platelets <100K, WBC < 
5 , 0 0 0 . 
( 4 . ) CyA as foilows-
P.O.D. * H : 2 mg/kg I.V. over 6 hr, 
P.O.D. * 2 : 1 2 mg/kg/day P.O. in 2 divided doses or 1.5 mg/kg I.V. q 12 hr, (If creatinine 
clearance < 25 m l / m i n o r serum Cr > 2 gm/dl, give 1 mg/kg I.V. or 8 mg/kg P.O.) 
P.O.D. * 3 : Decrease CyA dose by 1 mg/kg/day ( P . O . ) until a serum level determination 
J 
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Is made on day 3 - 5 , then adjust dose to obtain a serum trough value of 2 0 0 - 3 0 0 ng/ml, 
30 davs Post-Oo: Adjust dose to achieve a serum trough value of 5 0 - 1 5 0 ng/ml. 
Acute rejection first and second episode: 
( 1 . ) Methylprednlsolone Igm I.V. dally x 3 days, then give prednisone 1.0 mg/kg/day 
starting on day 4, Begin tapering If Bx. on day 5 - 7 shows resolution. Taper to 0.2 
mg/kg/day (to nearest 5mg)by day 12. Begin taper again on day 2 1 , patient off by day 28. 
P A T I E N T CROUPS ( f i g 1 0 ) 
There were as of September, 1986, three Immunosuppressant protocols in the UCTP 
plus the randomized vincristine study. 
Protocol * 1 - Standard prophylaxis with ATS. The "standard" regimen Indicated previously 
( 4 / 8 5 ) . ATG, CyA and azathioprine are used without "pulse" steroids unless rejection 
occurs. In addition, patients are randomized to receive VCR or continue standard therapy 
alone on day 9 post-transplant. Vincristine is given at 0.025 mg/kg I.V. (to a maximum 
one time dose of 2mg) on day 9. Patients are then given 0.025 mg/kg I.V. weekly for 3 
more doses, then every two weeks for 4 doses ( 8 total doses on days 9 , 16, 2 3 , 30, 4 4 , 
5 8 , 7 2 and 86), Dosage is reduced If peripheral neuropathy is suspected or total WBC 
drops below 3,000. 
Protocol *2-  Standard prophylaxis with ATQ plus pulse dose org! sterofe Beginning on 
day 8 , prednisone 1 mg/kg/day Is given In two divided dally doses for one week. Over the 
next two weeks the dose Is tapered by 0,07 mg/kg/day (to the nearest 5mg) until off, 
Patients are again randomized to vincristine as In protocol # 1 , 
Protocol -Comparison between ATQ or QKT? for early prophylaxis- This was a safety 
and efficacy study of 0KT3 for the early prophylaxis of acute rejection In cardiac allograft 
60 
transplantation. Several changes from the standard regimen were made here, This was an 
open-label trial using ATG as the control, given by the standard method. The patients were 
randomized according to availability of ATG which was recently limited due to production 
difficulties, Therefore more patients are in the 0 K T 3 arm of protocol 3, The second 
difference In protocol 3 is the use of low-dose prednisone ( 0 . 2 5 mg/kg/day) on days 2 - 1 4 , 
Then, prednisone at 1 mg/kg/day is begun on day 15 and tapered as in protocol 2, 
Cyclosporine administration is altered to start on day 4 at 6 mg/kg/day (no preoperative 
doses) and titrated to achieve serum concentrations of 1 0 0 - 2 0 0 n g / m l . Finally, patients 
are randomized to receive VCR on day 1 7 (vs, day 9) . VCR is given as in protocol * 1 . 
Only azathioprlne is unchanged from protocol * 1, The dose of Orthoclone 0KT3 is: 2 4 - 4 8 
hrs, post-op, 5mg I.V push daily x 14 days. P r i o r to the first three doses patients are 
pretreated with: hydrocortisone lOOmg I.V,, diphenhydramine 50mg I.V., ranitidine 
lOOmg I.V, and acetaminophen 650mg P.O. At 6 , 1 2 , and 18 hrs. post 0KT3 dose for the 
first three doses diphenhydramine 25mg I.V., ranitidine 50mg I.V. and acetaminophen 
650mgP,0. was given. 
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